SCHEMBL6017918

SCHEMBL6017918

CCOC(=O)c1nc(-c2c(OC)cccc2OC)n(C)c(=O)c1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 2/20 0.51
APLNR P35414 1/20 0.44
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 3/20 0.42
MAPT P10636 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ERCC1 P07992 1/20 0.41
FEN1 P39748 1/20 0.41
ERCC4 Q92889 1/20 0.41
CYP1A2 P05177 2/20 0.40
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
PABPC1 P11940 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
GAA P10253 2/20 0.40
ADORA3 P0DMS8 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6018051 0.87 ALDH1A1 (0.44) KDM4EALDH1A1ERCC1FEN1ERCC4
SCHEMBL6017939 0.84 KDM4E (0.43) KDM4EALDH1A1MAPTERCC1FEN1
SCHEMBL6017629 0.76 LMNA (0.48) KDM4EALDH1A1MAPTERCC1FEN1
SCHEMBL6017934 0.75 TSHR (0.46) CRHR1ALDH1A1MAPTMEN1KMT2A
SCHEMBL6018109 0.74 TRPV4 (0.35) KDM4EALDH1A1MAPTERCC1FEN1
SCHEMBL6018107 0.73 POLB (0.39) KDM4EALDH1A1MAPTERCC1FEN1
SCHEMBL6017926 0.73 TSHR (0.44) CRHR1ALDH1A1MAPTKMT2AGAA
SCHEMBL3060674 0.72 ALDH1A1 (0.44) KDM4EALDH1A1CYP1A2KMT2ARXFP1
SCHEMBL22079306 0.72 GABRG2 (0.50) KDM4EALDH1A1MAPTPOLBKMT2A
SCHEMBL31365377 0.72 GABRG2 (0.50) KDM4EALDH1A1MAPTPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037908-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2006-05-02 US disclosed
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY 2004-11-18 US disclosed
WO-2004096128-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex DUT, CDK6, TYMS CRHR1 3586/4885APLNR 3616/4885KDM4E 736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.